Figures & data
Figure 1. Antithrombotic effects of HLJDD in MCAO rats. (A) The dry weight of thrombus in arteriovenous shunt model at 24 h after MCAO surgery. (B) PT was determined in orbital blood at 24 h after MCAO onset. (C) The adhesion of blood platelet to collagen type I was determined with Tuszynski’s and Murphy’s method at 24 h after MCAO onset. (D) Platelet aggregation was measured by a turbidimetric method using a whole-blood aggregometer. The data expression method is mean ± SEM (n = 4). # denotes statistical significance (p < 0.05) compared with the normal group; *p < 0.05, significantly different from the model group by one-way ANOVA followed by post-hoc Student–Newman–Keuls test or unpaired and two-tailed Student's t-test.
Figure 2. HPLC analysis of HLJDD as the powder of the whole prescription. (A) Representative peaks of standard chemicals as the main ingredients of HLJDD. (B) HPLC chart of HLJDD was measured by DAD multi-wavelength detection at the wavelength of 260 nm.
Figure 3. Antiplatelet aggregation of main ingredients of HLJDD in MCAO rats. Platelet aggregation was measured by a turbidimetric method using a whole-blood aggregometer. The data expression method is mean ± SEM (n = 4). *p < 0.05, significantly different from the model group by one-way ANOVA followed by post-hoc Student–Newman–Keuls test or unpaired and two-tailed Student's t-test.
Data availability statement
Additional information and requests for data should be directed to the corresponding author X. Y. Chen ([email protected]).